Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30056523 | 1.00 | NOTUM (0.67) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL6097273 | 0.91 | NOTUM (0.58) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL8192396 | 0.87 | NOTUM (0.61) | NOTUMSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL16268868 | 0.83 | ALDH1A1 (0.64) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL20899542 | 0.83 | NOTUM (0.62) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL28208068 | 0.83 | NOTUM (0.62) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL28253827 | 0.83 | NOTUM (0.62) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL6102363 | 0.82 | ABHD6 (0.68) | NOTUMSMN1; SMN2TAAR1ABHD6MEN1 | |
| SCHEMBL29369046 | 0.82 | ESR2 (0.70) | NOTUMTAAR1ABHD6MEN1MAPT | |
| SCHEMBL1202402 | 0.82 | ESR2 (0.70) | NOTUMTAAR1ABHD6MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861527-B1 | Nitration in a static micromixer | MERCK PATENT GMBH (DE) | 2005-03-01 | — | — | US | claimed |
| EP-1200375-B1 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2004-09-22 | — | — | EP | claimed |
| JP-2003506340-A | — | — | 2003-02-18 | — | — | JP | claimed |
| EP-1200375-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GmbH (DE) | 2002-05-02 | — | — | EP | claimed |
| WO-2001009065-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2001-02-08 | — | — | WO | claimed |
| WO-2023207911-A1 | BICYCLIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION | 上海医药集团股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2022120048-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2021142444-A2 | PHOTOREDOX CATALYSTS AND METHODS OF USING SUCH CATALYSTS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021142444-A2 | PHOTOREDOX CATALYSTS AND METHODS OF USING SUCH CATALYSTS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2019242599-A1 | TETRAHYDRO ISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-12-26 | — | — | WO | disclosed |
| EP-2216312-B1 | PROCESS FOR PRODUCING ORGANIC COMPOUND | M TECHNIQUE CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1200375-B1 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004026896-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2004-04-01 | — | — | WO | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1200375-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GmbH (DE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009065-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | NOTUM 2404/4885SMN1; SMN2 2918/4885TAAR1 1744/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | NOTUM 2422/4885SMN1; SMN2 3361/4885TAAR1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.